iX Biopharma (SGX:42C) 3-Year EPS without NRI Growth Rate : 2.10% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is iX Biopharma 3-Year EPS without NRI Growth Rate?

iX Biopharma's EPS without NRI for the six months ended in Dec. 2023 was S$-0.01.

During the past 3 years, the average EPS without NRI Growth Rate was 2.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was 21.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 10 years, the highest 3-Year average EPS without NRI Growth Rate of iX Biopharma was 46.90% per year. The lowest was -19.70% per year. And the median was -4.60% per year.

Competitive Comparison of iX Biopharma's 3-Year EPS without NRI Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, iX Biopharma's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

iX Biopharma's 3-Year EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, iX Biopharma's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where iX Biopharma's 3-Year EPS without NRI Growth Rate falls into.

iX Biopharma 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

iX Biopharma (SGX:42C) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.

iX Biopharma 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of iX Biopharma's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

iX Biopharma (SGX:42C) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » iX Biopharma Ltd (SGX:42C) » Definitions » 3-Year EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Kim Seng Promenade, No. 14-01, Great World City East Lobby, Singapore, SGP, 237994

Website

https://www.ixbiopharma.com

iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in United States of America, Singapore, Australia, and China, of which the majority of the revenue comes from the United States of America. The company generates the majority of its revenue from the sale of specialty pharmaceutical products.

iX Biopharma (SGX:42C) Headlines

No Headlines